Procyon Advisors’s Abiomed Inc ABMD Stock Holding History

Procyon Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1	Closed	–	–	1142
2020 Q2	$0	Hold	1	–	–	﹤0.01%	1222
2020 Q1	$0	Hold	1	–	–	﹤0.01%	1195
2019 Q4	$0	Buy	+1	New	+$185	﹤0.01%	1095

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Procyon Advisors's ABMD Position: Q3 2020 in Review

Procyon Advisors sold out of Abiomed Inc (ABMD) in Q3 2020, closing a stake of 1 share.

Procyon Advisors first reported a position in ABMD in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q2 2020. 498 funds tracked by Wall St. Rank hold ABMD as of Q3 2020.

Procyon Advisors reported no remaining Abiomed Inc position as of Q3 2020 after selling out during the quarter.
Procyon Advisors sold 1 Abiomed Inc share in Q3 2020.
Procyon Advisors first reported a position in Abiomed Inc in Q4 2019 and held it in 3 quarters.
Procyon Advisors's Abiomed Inc position peaked at $0 in Q2 2020.
498 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.